SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that CEO M. Scott Salka will present a company overview at the 7th Annual LD Micro Invitational Conference at the Luxe Hotel in Los Angeles on Tuesday, June 6, 2017, at 4:30 p.m. Pacific Time.
“We look forward to discussing our new strategic emphasis on utilizing our proprietary bacteriophage technology to develop personalized, precision phage therapies for patients who suffer from serious or life-threatening multidrug-resistant (MDR) bacterial infections and have limited or no satisfactory treatment options,” said Mr. Salka. “Our technology is well suited for precision medicine in infectious diseases due to its highly selective spectrum of activity, potential efficacy against MDR bacteria and inherent qualities, which enable ‘real-time’ manufacturing of customized therapies.”
AmpliPhi’s new strategic emphasis on personalized medicine builds upon the Company’s prior successes in developing tailored bacteriophage therapies under emergency investigational new drug (IND) applications for a critically ill, comatose patient with an MDR Acinetobacter baumannii infection and for a patient with an MDR Pseudomonas aeruginosa infection in the bladder.
Management will be available for one-on-one meetings with the investment community on June 6 and 7. Please contact LD Micro via the conference website or LHA at 310-691-7100 to arrange a meeting.
A live webcast of the presentation will be accessible from the Company’s website at http://investor.ampliphibio.com/events-and-presentations and a replay will be available for 30 days following the presentation.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.
AmpliPhi recently announced the closing of an underwritten public offering for net proceeds of approximately $9.1 million.
More information is available at www.ampliphibio.com.
Forward Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics, the potential benefits of phage therapy, AmpliPhi’s development of bacteriophage-based therapies, and AmpliPhi’s personalized phage therapies strategy, including the expected benefits therefrom. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in these forward-looking statements are risks and uncertainties associated with AmpliPhi’s business and financial condition and the other risks and uncertainties described in AmpliPhi’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, as filed with the SEC, and AmpliPhi’s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.